Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocitic leukemia cells

2014 ◽  
Vol 93 (11) ◽  
pp. 1819-1823 ◽  
Author(s):  
Massimo Breccia ◽  
Maria Stefania De Propris ◽  
Caterina Stefanizzi ◽  
Sara Raponi ◽  
Matteo Molica ◽  
...  
Blood ◽  
1988 ◽  
Vol 72 (5) ◽  
pp. 1580-1588 ◽  
Author(s):  
S Saeland ◽  
C Caux ◽  
C Favre ◽  
JP Aubry ◽  
P Mannoni ◽  
...  

Abstract Induction of proliferation and differentiation in response to recombinant human interleukin-3 (hIL-3) was studied in liquid and semisolid cultures of umbilical cord blood and bone marrow cells that were fractionated by “panning” with anti-My10 antibody according to expression of CD34 antigen. Cells from enriched fractions (70% to 90% CD34+) were found to proliferate strongly in response to hIL-3. Phenotypic analysis and morphologic characterization of the proliferating cells demonstrated a rapid decrease in CD34+ cells and an exponential increase in the number of cells belonging to the neutrophilic, eosinophilic, monocyte/macrophage, and thrombocytic lineages. When combined with recombinant human erythropoietin, burst colonies and cells expressing glycophorin-A were detected, thereby demonstrating the effects of hIL-3 on erythroid progenitors. Further, the development of mixed-erythroid colonies indicated that multipotential cells within CD34-enriched fractions responded to hIL-3. In addition, we examined the effect of hIL-3 on the proliferation of primary acute myeloblastic leukemia cells in liquid culture. We found that hIL-3 was able to induce cell proliferation in a proportion of the cases tested. Heterogeneity of the responses to hIL-3 was in part related to French-American-British classification but could not be correlated with CD34 antigen expression by the leukemic cells. These results indicate that, although the effects of hIL-3 on proliferation and differentiation of cells obtained from normal hematopoietic specimens were primarily borne by CD34+ cells, expression of the CD34 molecule per se is an insufficient condition to determine a growth response to this lymphokine.


Blood ◽  
1988 ◽  
Vol 72 (5) ◽  
pp. 1580-1588
Author(s):  
S Saeland ◽  
C Caux ◽  
C Favre ◽  
JP Aubry ◽  
P Mannoni ◽  
...  

Induction of proliferation and differentiation in response to recombinant human interleukin-3 (hIL-3) was studied in liquid and semisolid cultures of umbilical cord blood and bone marrow cells that were fractionated by “panning” with anti-My10 antibody according to expression of CD34 antigen. Cells from enriched fractions (70% to 90% CD34+) were found to proliferate strongly in response to hIL-3. Phenotypic analysis and morphologic characterization of the proliferating cells demonstrated a rapid decrease in CD34+ cells and an exponential increase in the number of cells belonging to the neutrophilic, eosinophilic, monocyte/macrophage, and thrombocytic lineages. When combined with recombinant human erythropoietin, burst colonies and cells expressing glycophorin-A were detected, thereby demonstrating the effects of hIL-3 on erythroid progenitors. Further, the development of mixed-erythroid colonies indicated that multipotential cells within CD34-enriched fractions responded to hIL-3. In addition, we examined the effect of hIL-3 on the proliferation of primary acute myeloblastic leukemia cells in liquid culture. We found that hIL-3 was able to induce cell proliferation in a proportion of the cases tested. Heterogeneity of the responses to hIL-3 was in part related to French-American-British classification but could not be correlated with CD34 antigen expression by the leukemic cells. These results indicate that, although the effects of hIL-3 on proliferation and differentiation of cells obtained from normal hematopoietic specimens were primarily borne by CD34+ cells, expression of the CD34 molecule per se is an insufficient condition to determine a growth response to this lymphokine.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2848-2848
Author(s):  
Emmanuelle Tavernier ◽  
Amelie Duval ◽  
Jerome Cornillon ◽  
Pascale Flandrin ◽  
Denis Guyotat ◽  
...  

Abstract CXC chemokine receptor 4 (CXCR4) is the receptor for stromal derived factor (SDF-1 or CXCL12) and plays a crucial role in the homing of leukemia cells within the marrow microenvironment. Adhesion to marrow stromal cells is essential for the survival and proliferation of acute myelogenous leukemia (AML) cells, and protect AML cells from chemotherapy-induced apoptosis. In the same way, heat shock proteins (HSP) act as molecular chaperones and are involved in signalling pathways for cell proliferation and survival. HSP have a role in the modulation of apoptosis and are implicated in the resistance of leukemia cells to therapeutic drugs. The aim of this work was to assess the prognostic impact of CXCR4, adhesion molecules such as Very Late Antigen-4 (VLA-4) and Focal Adhesion Kinase (FAK), and HSP expression (HSP 27, HSP 70, HSP 90). In this study, we retrospectively analysed, by flow cytometry, the “adhesive” phenotype and the HSP expression in AML cells from 36 patients treated between 04/1998 and 03/2002. These patients presented de novo AML, and favourable, intermediate and adverse cytogenetics were observed in 7, 19 and 10 patients respectively. Study of the adhesive phenotype was repeated for 10 patients at time of relapse and compared to adhesive phenotype at diagnosis. The flow cytometry analysis was performed with a FACS Canto: conjugated antibodies were used in combination with anti-CD34-FITC and anti-CD45-APC. Twenty-eight of the 36 patients achieved complete remission (CR) whereas seven patients were refractory to the chemotherapy and one patient died from toxicity during aplasia. Median overall survival (OS) was 19.4 months (95% CI: 0.25–102 months). In univariate analysis, the two main prognostic factors in terms of CR achievement were lower CXCR4 and VLA-4 expression on leukemia cell surface (p = 0.03 and p = 0.05 respectively). Overall survival (OS) was negatively influenced by higher CXCR4 expression (p = 0.01), higher VLA-4 expression (p = 0.01), higher FAK expression (p = 0.04) and higher HSP90 expression (p = 0.04) by leukemia cells at diagnosis. Patients were secondarily distributed in two prognostic groups: - Group A including 26 patients presenting overexpression of 0, 1 or 2 factors within CXCR4, VLA-4, FAK, HSP 90 - Group B including 10 patients with overexpression of 3 or 4 factors. Group B is associated with significantly shorter OS. In multivariate analysis, FAK overexpression and HSP90 overexpression remained of prognostic value for OS (p = 0.01 and p = 0.03 respectively). Moreover, when comparing the adhesive phenotype for 10 patients between diagnosis and relapse, we noted that CXCR4 and VLA-4 are overexpressed at time of relapse (91% positive cells versus 26% at diagnosis for CXCR4 (p = 0.008), and 88% versus 21% for VLA-4 (p = 0.008)). In conclusion, CXCR4, adhesion molecules and HSP90 are new phenotypic prognostic markers. These data indicate that it should be interesting to determine CXCR4, VLA-4, FAK and HSP 90 in the routine flow cytometry diagnostic of AML in order to establish risk-stratified therapeutic strategies. A prospective study with a larger series of patients may lead to confirm the prognostic value of these markers. Figure Figure


1992 ◽  
Vol 8 (4-5) ◽  
pp. 337-344 ◽  
Author(s):  
D. Robert Sutherland ◽  
Mary Jo Fackler ◽  
W. Stratford May ◽  
Kathryn E. Matthews ◽  
Michael A. Baker

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5641-5641
Author(s):  
Lin Yang ◽  
Sara Beiggi ◽  
Yunli Zhang ◽  
Robert Schmidt ◽  
Spencer B Gibson ◽  
...  

Abstract Introduction: In chronic lymphocytic leukemia (CLL), short telomere length in the leukemia cells predicts poor prognosis. However, it is not known whether telomere length in normal tissues also predicts patient outcome and can improve the prognostic value of CLL telomere length. Prognosis in CLL is heterogeneous with the primary cause of death being cancer and infections, thought related to immunosuppression. The elderly, males and those with comorbidities have a particularly poor relative survival. Whether this reflects differences in the biology of CLL in these patient groups, or to extrinsic factors such as increased immunosuppression or fragility, is unknown. In normal individuals, the telomeres in somatic cells (ie, buccal cells (BC)) shorten with aging and prior comorbidities; short telomeres being predictive of early mortality related to infections, cancer and cardiovascular disease. In the present study, we have evaluated BC telomere length in patients with CLL, to determine if this is predictive of survival, and can enhance the predictive value of leukemia cell telomere length. Methods: The Manitoba CLL tumor bank contains 235 samples from newly diagnosed CLL patients between 2007-2011; with a median follow-up of 2 years. One-quarter of these patients required chemotherapy and one-tenth have died. Genomic DNA was extracted from purified CLL cells and buccal cells (BC) collected at diagnosis. Telomere length was established by multiplex quantitative real-time PCR. Telomere/standard (t/s) ratio was calculated using the beta-globulin gene as the standard. Statistical analysis was performed using Statistical Analysis Software (SAS) and Prism software. Results: The median adjusted telomere length was much shorter in CLL cells than in BCs being 0.53 and 2.01, respectively. In BCs, telomere length significantly shortened with increasing age (OR 1.04, CI 95% (1.00-1.078)) and at this short follow-up time, correlation with second malignancies was approaching significance (p=0.06). However, BC telomere length was not reflective of the number of comorbidities or survival. In contrast, telomere length in CLL cells was independent of age (p=0.44) and sex (p=0.75) confirming that these factors did not influence the cellular biology of the disease. Telomere length also correlated with other biological markers with short telomeres correlating with unmutated IgHV status (p<0.0001), Zap-70 positivity (p=0.05), and CD38 positivity (p=0.003). These patients with short telomeres also had clinical markers of poor prognosis including short lymphocyte doubling time (p=0.004), higher Rai stage (p=0.02) and an earlier time to treatment (p<0.0001). The prognostic value of CLL telomere length was not enhanced by the addition of BC telomere length. Conclusions: These results demonstrate that BC telomere length in CLL patients shorten with age, and short telomeres may predict subsequent second malignancies. Telomere length in CLL cells correlates with biological and clinical markers of aggressive disease, but it does not explain the poor prognosis seen in the elderly and male patients. While BC telomere length does not seem to influence the initial clinical course of CLL, ongoing studies are evaluating whether it is predictive of the long-term risk of infections and second malignancies. In addition, whether BC telomere length in CLL is shorter than in the normal population and whether shortening correlates with specific comorbidities is presently being determined. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1365-1365
Author(s):  
Satoki Nakamura ◽  
Takaaki Ono ◽  
Yuya Sugimoto ◽  
Miki Kobayashi ◽  
Naohi Sahara ◽  
...  

Abstract Purpose: The protein p27 is an important regulator of cell cycle. An increase in p27 causes proliferation of cells, while a decrease in p27 induces quiescence of cells. p27 is regulated by transcriptional, translational and proteolytic mechanisms. Among them, an importnant mechanism in the regulation of p27 is proteolysis. Kinase interacting with stathmin, KIS, is a serine / threonine kinase, and regulates cell cycle progression through the phosphorylation of p27 on serine 10. The S10 phosphorylation on p27 plays an important role in p27 degradation. KIS that phosphorylates p27 on S10 and its role in the regulation of cell cycle progression have not been defined in leukemia cells. In this study, we investigated the role of KIS in leukemia cells. Materials and Methods: We examined the biological significance of KIS expression in K562, NB4, U937, CEM, MOLT4, and SUP-B15 leukemia cells and relationship with the G1 regulaters, such as p27. Moreover, we generated the lentivirus vector inserted with the dsDNA of KIS small interfering RNA (siRNA), and effects of down-regulation of KIS by siRNA transfection were investigated in leukemia cells. Results: RT-PCR and western blot analysis showed high KIS expression in all leukemia cells. The p27 phosphorylation on S10 was significantly lower in the leukemia cells transduced with KIS siRNA and depletion of KIS enhanced growth arrest. The down-regulation of KIS induced G1 arrest in cell cycle, but not apoptosis. In cell cycle analysis, control leukemia cells showed 42.3 ± 1.8 %, but leukemia cells transfected with KIS siRNA showed 67,1 ± 2.1 % in G1 fraction. Moreover, these cells significantly showed small population in S ansd G2 fractions compared compared with controls. Conclusion: These findings suggest KIS expression promotes cell cycle progression in leukemia cells. Depletion of KIS using siRNA in leukemia cells induced cell cycle arrest in G1 phase compared with control cells. In this study, we showed that KIS might be the target for the molecular therapy.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 990-990
Author(s):  
Lueder H. Meyer ◽  
Leonid Karawajew ◽  
Martin Schrappe ◽  
Wolf D. Ludwig ◽  
Klaus M. Debatin ◽  
...  

Abstract Drug resistance and treatment failure in acute leukemia may be attributed to apoptosis resistance in leukemia cells since defects in apoptosis signal transduction are commonly acquired during malignant transformation. Expression analysis of single molecules with regard to clinical outcome could so far not identify common apoptosis defects with prognostic value in primary acute leukemias. We addressed the role of apoptosis signaling for the initial response to induction treatment in pediatric B precursor lymphoblastic leukemia by functional assays. Apoptosis signaling in response to survival factor withdrawal was assessed in 82 primary leukemia samples by measurement of the key apoptotic events, caspase-3 activation and mitochondrial cytochrome c release. Caspase-3 activation directly correlated to the initial response to treatment assessed by the percentage of leukemia cells in bone marrow on day 15 (p = 0.015). Intact apoptosis signaling was indicated by a significant correlation of caspase activation and cytochrome c release was found especially in the groups of good responding patients (rs 0.375 – 0.502; p = 0.001). Interestingly, this correlation was completely absent in all groups of poor responding patients defined by insufficient leukemia cell reduction on day 8, 15 or 33. The efficacy of apoptosis signal induction in the individual leukemia is expressed by the parameter CRAC (Cytochrome c Related Activation of Caspase-3), relating the extent of caspase activation to cytochrome c release in a single patient sample. Ten of twelve patients with prednisone poor response (chi square, p= 0.031) and all patients not achieving remission on day 33 (4 of 4) had negative CRAC values, indicating deficient cytochrome c related caspase activation. Furthermore, the CRAC negative group revealed significant higher percentages of leukemia cells in bone marrow on day 15 (n=37, mean 22.8) than the CRAC positive patients (n=30, mean 6.2, p = 0.004). In addition all four relapse patients showed negative CRAC values indicating a prognostic value beyond initial treatment response. The data show that the intact relation of cytochrome c release and caspase activation indicating an intact apoptosome function is important for efficient remission induction treatment in childhood B precursor ALL. Assessment and quantification of this relation for individual patients by the parameter CRAC may serve as potential factor for treatment stratification.


Tumor Biology ◽  
2017 ◽  
Vol 39 (3) ◽  
pp. 101042831769455 ◽  
Author(s):  
Magdalena Witkowska ◽  
Agata Majchrzak ◽  
Barbara Cebula-Obrzut ◽  
Ewa Wawrzyniak ◽  
Tadeusz Robak ◽  
...  

The SMAD proteins are responsible for transducing signals from activated transforming growth factor-beta. This is the first study assessing the expression of SMAD-1/8, SMAD-2/3, SMAD-4, and SMAD-7 in chronic lymphocytic leukemia cells with regard to their clinical significance and potential prognostic value. Overexpression of SMAD-1/8 was observed in 160 chronic lymphocytic leukemia patients compared to 42 healthy volunteers (p = 0.023) and was associated with a more progressive course of the disease (p = 0.016). Moreover, the high expression of SMAD-1/8 correlated with other, well-established prognostic factors, including clinical stage (p = 0.010) and lymphocyte doubling time (p = 0.021). The expression of SMAD-4 was lower in chronic lymphocytic leukemia patients compared with the control group (p = 0.003). Importantly, lower SMAD-4 levels correlated with longer progression-free survival (p = 0.009), progressive course of the disease (p = 0.002), advanced clinical stage (p = 0.0004), elevated beta-2-microglobulin and lactate dehydrogenase levels (p < 0.05), shorter lymphocyte doubling time (p = 0.009), and CD38 antigen expression (p = 0.039). In addition, lower SMAD-4 expression correlated with lower apoptotic index (p = 0.0007) and lower expression of receptors for vascular endothelial growth factors VEGFR-1 and VEGFR-2. A significant association was found between the low expression of inhibitory protein SMAD-7 and both zeta-chain-associated protein kinase 70–negative cells (p = 0.04) and lower apoptotic index (p = 0.004). No differences were observed in SMAD-2/3 expression. In conclusion, our results demonstrate a significant correlation between greater SMAD-1/8 and lower SMAD-4 expression in chronic lymphocytic leukemia cells, as well as more progressive outcome and poor prognosis. These data provide supporting evidence that the expression of SMAD proteins plays an important role in disease development and may be considered as a novel, biologic prognostic factor in this disease.


Author(s):  
T. Aoki ◽  
J. Izard ◽  
U. Hämmerling ◽  
E. de Harven ◽  
L. J. Old

Although a variety of viral and cellular antigens have been demonstrated by ferritin-labeled antibody, this technique has not been used to locate isoantigens on the surface of nucleated cells. The recognition of several systems of isoantigens on the surface of thymocytes, lymphocytes and leukemia cells of the mouse and the ease with which these cells can be obtained in free suspension led us to consider the ferritin-labelling method to determine the amount and location of these isoantigens on the cell surface. Because of the problems involved in the direct labelling of mouse gamma globulin by ferritin, we have chosen an indirect labelling technique (i.e. ferritin-conjugated rabbit anti mouse γG)to detect localization of mouse isoantibody.


Sign in / Sign up

Export Citation Format

Share Document